TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03939819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViSiGi® 3D suction calibration device
Description: ViSiGi 3D®is a non-sterile, single patient use device. The device comprises a tube with a closed, rounded tip, and holes at the distal end. The proximal end of ViSiGi 3D® includes an integral suction regulator and vented On/Off valve.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagogastroduodenoscopy (EGD) calibration
Description: Gastroscope is an illuminated optical, slender and tubular instrument (a type of borescope) used in esophagogastroduodenoscopy.
Study: NCT02040883

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole
Description: Treated with a stable dose of an AAPD for at least three months before enrollment, which is suggested to attain the stable cognitive status.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole
Description: Treated with a stable dose of an AAPD for at least three months before enrollment, which is suggested to attain the stable cognitive status.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tandospirone
Description: Tandospirone，30mg per day
Study: NCT04213287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen Trometamol
Description: Drug: Dexketoprofen Trometamol oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen Trometamol
Description: Drug: Dexketoprofen Trometamol oral tablet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: Drug: heavy bupivacaine 2,5 ml 0,5%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: Drug: heavy bupivacaine 2,5 ml 0,5%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IPACK
Description: Drug: bupivacaine 20 ml 0,025%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPACK
Description: Drug: bupivacaine 20 ml 0,025%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAI
Description: Drug: bupivacaine 30 ml 0,025%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block
Description: Drug: bupivacaine 20 ml 0,025%
Study: NCT02320695

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isopropyl Alcohol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pain Relieving Cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic/Pain Relieving Ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Original Ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pain Relief Ointment
Study: NCT03093493

Intervention type: DIAGNOSTIC_TEST
Intervention: Genotyping
Description: Genotyping by next generation sequencing

Intervention type: DIAGNOSTIC_TEST
Intervention: Genotyping
Description: Genotyping by next generation sequencing
Study: NCT02200367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-mental health collaborative programme

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Study: NCT00448253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NP-015
Description: Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA, or placebo.~And a Fourth Cohort at 840 units TNA with 2 additional product lots.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: NP-015
Description: Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA, or placebo.~And a Fourth Cohort at 840 units TNA with 2 additional product lots.
Study: NCT03878017

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin marking of clip axillary lymph node for localisation
Description: to determine the feasibility of skin marking to localize clipped ln
Study: NCT02568917

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment - Ketac Molar Easy Mix
Description: Occlusal and occlusal-proximal ART restorations in primary and permanent molars using the high viscosity GIC Ketac Molar Easy mix will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Restoration - Composite Resin (Bulk Fill)
Description: Occlusal and occlusal-proximal composite resin restorations in primary and permanent molars using the Scotchbond Multi-purpose adhesive system and the Filtek Bulk Fill composite resin wil be performed. Local anesthesia can be used if necessary. Access to caries lesion will be done using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked.
Study: NCT04081597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Star-101
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT01019486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson myocardial perfusion imaging
Description: Myocardial perfusion imaging at rest and following 400mcg Regadenoson IV bolus pharmacologic stress with 30 mCi of Tc-99m sestamibi injected at both but the studies performed 48 hours apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson myocardial perfusion imaging
Description: Myocardial perfusion imaging at rest and following 400mcg Regadenoson IV bolus pharmacologic stress with 30 mCi of Tc-99m sestamibi injected at both but the studies performed 48 hours apart.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson MRI myocardial blood flow
Description: CMR assessment of stress myocardial perfusion and blood flow after 400 mcg Regadenoson pharmacologic using gadolinium contrast (gadoteridol) 0.05mmole/kg at stress and rest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson MRI myocardial blood flow
Description: CMR assessment of stress myocardial perfusion and blood flow after 400 mcg Regadenoson pharmacologic using gadolinium contrast (gadoteridol) 0.05mmole/kg at stress and rest.
Study: NCT04428684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pepti 3.6 mg
Description: Each patient receives one injection of Pepti 3.6mg or Zoladex 3.6mg on Day 0 and a second injection of the same drug given the first time on Day 28. On Day 42 patients undergo endometrial ablation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pepti 3.6 mg
Description: Each patient receives one injection of Pepti 3.6mg or Zoladex 3.6mg on Day 0 and a second injection of the same drug given the first time on Day 28. On Day 42 patients undergo endometrial ablation
Study: NCT03512184

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: YMCA class
Description: The Gastroenterologists of Weill Cornell Medical College that are associated with this trial want to implement the YMCA's DPP in the NAFLD population as a structured lifestyle modification/educational intervention. The hypothesis is that the NAFLD patients who complete the YMCA's DPP will also have weight loss and improvement in hepatic steatosis. Importantly, positive results in this New York City-based pilot study would provide a strong rationale for determining whether such a program could be useful to treat NAFLD at established YMCA DPP sites across the country.
Study: NCT02341521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC000459
Description: Taken orally for 8 days
Study: NCT04661592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroCatch Platform
Description: To elicit the ERP components of interest in this study (N100, P300, N400), proprietary auditory stimulus sequences will be administered using the NeuroCatch™ Platform version 2.0, an investigational medical device. Each sequence consists of tones and word pairs to elicit the various components of interest. Version 2.0 of the NeuroCatch™ Platform consists of a computerized acquisition software which presents the stimulus, acquires the data and presents the amplitude and latency values of the ERP components (N100, N400, P300)
Study: NCT02230618

Intervention type: DRUG
Intervention: insulin degludec/insulin aspart
Description: Ryzodeg™ will be prescribed by the physician under normal clinical practice conditions and will be obtained/purchased from the chemist based on physician prescription. No treatment given.
Study: NCT00285584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Participants initially received bupropion, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage of bupropion allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants initially received placebo, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
Study: NCT02681484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anthroposophic speech therapy
Description: Anthroposophic speech therapy uses sound-combinations like KLSFM or OM and hexameter verse in German, spoken by the therapist and imitated by the patients, to expand and decelerate respiration. The intervention is conducted by the same qualified therapist for one patient in different days but during the same daytime for 30 minutes in upright position and walking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anthroposophic speech therapy
Description: Anthroposophic speech therapy uses sound-combinations like KLSFM or OM and hexameter verse in German, spoken by the therapist and imitated by the patients, to expand and decelerate respiration. The intervention is conducted by the same qualified therapist for one patient in different days but during the same daytime for 30 minutes in upright position and walking.
Study: NCT01139684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Repeated sprint test
Study: NCT01668121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort Turbohaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbohaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide/formoterol Easyhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol Easyhaler
Study: NCT01797926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Treatment: 5 mg amlodipine + 50 mg losartan
Description: Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 50 mg losartan tablet administered orally in fasted state as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Treatment:5 mg amlodipine + 100 mg losartan
Description: Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 100 mg losartan tablet administered orally in fasted state as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC 5/50 amlodipine/ losartan
Description: Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 50 mg losartan in fasted state
Study: NCT02232360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin and fenofibrate
Description: Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin alone
Description: Rosuvastatin 10mg per day
Study: NCT03532360

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral immunotherapy
Description: Starting from a very low level and over a period of several months, participants receive escalating doses of the food to which they are allergic

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral immunotherapy
Description: Starting from a very low level and over a period of several months, participants receive escalating doses of the food to which they are allergic
Study: NCT04689009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EmoLED
Description: The treatment with EmoLED, in addition to the SOC, will be performed during each visit for 60 seconds on each 5 cm diameter sub-area of the selected lesion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: current Standards Of Care
Description: The lesions will be cleansed with saline solution and, if necessary, surgical debridement will be performed with the most suitable method. At this point, if patient is included in EmoLED Group, the EmoLED treatment starts. After EmoLED application (EmoLED Group) or after cleansing (SOC Group), a polyurethane foam dressing will be applied on the lesion. In case of clinical signs of infection, a silver dressing will be applied.~Then an elasto-compressive double layer dressing of the limb with cohesive fixation bielastic latex-free bandage will be carried out.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: current Standards Of Care
Description: The lesions will be cleansed with saline solution and, if necessary, surgical debridement will be performed with the most suitable method. At this point, if patient is included in EmoLED Group, the EmoLED treatment starts. After EmoLED application (EmoLED Group) or after cleansing (SOC Group), a polyurethane foam dressing will be applied on the lesion. In case of clinical signs of infection, a silver dressing will be applied.~Then an elasto-compressive double layer dressing of the limb with cohesive fixation bielastic latex-free bandage will be carried out.
Study: NCT03781336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based self care
Description: Experimental: an abridged mindfulness-based program that is incorporated into the work day, which consists of five weekly 1.5 hour sessions.
Study: NCT01797926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC 5/100 amlodipine /losartan
Description: Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 100 mg losartan in fasted state
Study: NCT03179449

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic (ferumoxytol-enhanced MRI)
Description: Undergo ferumoxytol-enhanced MRI
Study: NCT02348021

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous coronary intervention (PCI)
Study: NCT03179449

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Undergo surgical resection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue Analysis
Description: Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
Study: NCT04431414

Intervention type: OTHER
Intervention: Sample collection
Description: * blood, nasal swab, nasal wash, and saliva~* optional stool swab

Intervention type: OTHER
Intervention: Sample collection
Description: * blood, nasal swab, nasal wash, and saliva~* optional stool swab
Study: NCT02348021

Intervention type: DRUG
Group type: OTHER
Intervention: Dual Anti Platelet Therapy
Description: All patients will receive Dual Anti Platelet Therapy for one month
Study: NCT04431414

Intervention type: OTHER
Intervention: Sample collection
Description: * blood, nasal swab, nasal wash, and saliva~* optional stool swab
Study: NCT01699919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous lignocaine
Description: Intravenous lignocaine infusion is given in intraoperative period and till one hour post surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous lignocaine
Description: Intravenous lignocaine infusion is given in intraoperative period and till one hour post surgery.
Study: NCT03637699

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Positive Psychology
Description: 5-week positive psychology intervention
Study: NCT03015714

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MIRT
Description: MIRT consists of a 4-week rehabilitation program in a hospital setting, which entails four daily sessions of physical therapy for five days and one hour of physical exercise on the sixth day. On the seventh day the patient rests. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with a physical therapist. The second session includes aerobic exercises to improve balance and gait, using different devices: a stabilometric platform with visual cues, a treadmill plus and a cycloergometer. The third session consists of occupational therapy, the fourth one includes one hour of speech therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MIRT-AT
Description: Patients in the MIRT-AT group will undergo the land-based therapy described in MIRT plus three sessions per week (Monday, Wednesday, Friday) of aquatic therapy. On days of aquatic therapy the first session of MIRT was not provided. The aquatic therapy program included aerobic exercises and physical activities to improve balance, motor skills, coordination and joints mobility. The water sessions were divided into 3 phases: i) Warm Up Exercises, ii) Central session Training, iii) Cool-down.
Study: NCT03934749

Intervention type: DEVICE
Intervention: Non Invasive Ventilation
Description: NIV using standard mode or Lowenstein mode

Intervention type: DEVICE
Intervention: Non Invasive Ventilation
Description: NIV using standard mode or Lowenstein mode
Study: NCT01784198

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Intake
Description: Oral consumption of Eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
Study: NCT02390648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginger
Description: Ginger capsule (500 mg) taking twice a day by mouth during the first 5 days of chemotherapy cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule taking twice a day by mouth during the first 5 days of chemotherapy cycle
Study: NCT01216098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doula support
Description: A doula is a paraprofessional who provides continuous emotional and physical support to women and their families during the intrapartum period.
Study: NCT01413282

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac CT
Description: Calcium scan and CT coronary angiography
Study: NCT04373382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Resilience Champion
Description: PRC is supplied to everyone and provides support to hospital staff during the COVID-19 pandemic in a stepped-wedge design.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enriched Survey Feedback
Description: This intervention provides feedback based on answers to questionnaires to those in the Enriched Feedback arm of the study.
Study: NCT01839370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed Loop with Pramlintide
Description: A closed-loop automated insulin management system (Adaptive Insulin Meal Supervisor- AIMS) for meals utilizing continuous glucose monitoring (CGM)and subcutaneous insulin pump and a standard pramlintide therapy will be compared to a standard pramlintide therapy alone to control glucose levels in individuals with type 1 diabetes. DiAs is controlled by the subject, with assistance from the study personnel as needed.
Study: NCT03044145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Cultural Formulation Interview-Engagement Aid
Description: Culture affects how all people communicate and understand the world. Culture is important because patients and clinicians from different cultural backgrounds may have different preferences for communication. Mismatch in the clinician's approach and the patient's expectations of care can lead to patient dissatisfaction and discontinuation with treatment. Patients and clinicians may also have different views about what caused an illness, how it functions, what makes it better or worse, and the types of treatment needed. The CFI-EA is a series of questions over three sessions that clinicians can use to clarify patient views about treatment and communication so that patients stay in treatment longer. Clinicians can use the CFI-EA to customize their current treatment plans.
Study: NCT03246906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO
Study: NCT00817830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lodenafil carbonate
Description: Patients will do a cardiopulmonary exercise test after placebo administration. Seven days later, a new cardiopulmonary test should be done using lodenafil carbonate, 80mg, orally.
Study: NCT03956641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptated Physical Activity
Description: Evaluation of the physical condition and the quality of life during the course of treatment (after 8 weeks of treatment) and at the end of the treatment's line (except for breast cancer patients)